



Executive summary

Reinventing MedTech with intelligent technologies

Human-centric healthcare for
tech-savvy patients and organizations




Introduction

Today's patients prefer the convenience and immediacy of technology that helps them access real-time medical information. Our research, which included 800 U.S. patients aged 13 to 72, found that 94% leverage devices and apps to manage their health conditions¹, signaling a growing market demand.


Just as intelligent technologies such as predictive and generative AI are bolstering patient awareness and behaviors, they are also opening new possibilities for MedTech companies to serve cash-strapped healthcare providers. These providers are dealing with acute talent shortages and need to deliver more efficient and effective care across a growing array of settings, ultimately leading to cost savings.

To thrive in this transformative landscape, MedTech companies must prioritize investment in new capabilities while lowering costs across the care continuum. A robust digital core, integrating cloud, data and AI, is essential for rapid development of new capabilities and driving enterprise-wide operational efficiency.

To better understand how leading MedTech companies can navigate this new future, Accenture has explored four segments—diabetes, cardiovascular (CVD), general surgery and diagnostic imaging—through expert research. This report delves into how leading MedTech companies can seize the opportunities of this digital era, offering in- depth analyses of key segments and actionable strategies for sustainable competitive advantage.



Strategic pivot in response to changing market dynamics



The shift to preventative care unlocks new value pools

Create new opportunities to move upstream in the patient care pathway




Intelligent technologies create opportunities to revolutionize daily operations

Disrupt the MedTech value chain model by automating, augmenting, and reinventing traditional workflows and drive top and bottom-line improvements




Intelligent technologies power new smart connected solutions

Enhance the core product portfolio and create new revenue streams



Business model innovation fuels growth despite cost pressures and shifts in care

Promote a shift towards modern, less infrastructure dependent business models



Connected ecosystem across care continuum requires a broader set of capabilities

Deepen internal & external ecosystem partnerships to benefit broader care continuum solutions

Cost efficiencies driven by gen AI across enterprise operations

Trends	Diabetes	Cardiovascular	General surgery	Diagnostic imaging
The shift to preventative care unlocks new value pools	Disruptors are leveraging the idea of turning a medical device into a consumer product Consumer lifestyle solutions30% Preventative solutions21%	Upstream care is gaining attention in CVD Diagnostics97% Monitoring93% Screening90% Early intervention76%	Almost all CXOs agree to allocate more R&D spend to upstream care and seven in 10 are allocating more capital budget R&D spend90% Capital budget70%	Similar to general surgery, CXOs agree to allocate more funds to R&D and capital budgets for upstream solutions R&D spend83% Capital budget67%
	CXOs believe if no action is taken, it could negatively affect their revenues by 3–5% in the next five years	CXOs rate high revenue generation potential in upstream care in next three years	CXOs note a shift in resource allocations for upstream care compared to three years ago	CXOs note a shift in resource allocations for upstream care compared to three years ago
Intelligent technologies create opportunities to revolutionize daily operations	• Drive sales and customer support, assist regulatory filings • Help reduce R&D costs and failure events, avoid product recalls	• Assess demand for cardiac devices in a specific region by analyzing internal data and external data • Help derive quick, dependable insights from the vast amount of data, improve design effectiveness	• Analyze various parameters such as ergonomics to optimize design • Customize specialized general surgery devices through data analysis and pattern recognition	• Drive sales and customer support, assist regulatory filings • Develop personalized imaging protocols by analyzing patient-specific data

Technological advancements and business model disruption will be critical to maintain and grow share in the evolving landscape

Trends	Diabetes	Cardiovascular	General surgery	Diagnostic imaging
Intelligent technologies power new smart connected solutions	- Provide personalized guidance for diabetes management - Identify trends, anomalies, and potential health risks, enabling early intervention	- Identify trends, anomalies, and potential health risks, enabling early intervention Develop gen AI-powered platforms	- Assist in postoperative analysis by processing patient recovery data - Program surgical robots and analyze data from sensors to enable robots to adapt changing conditions	Streamline workflow processes, automating routine tasks - Improve the quality of medical images by reducing noise, enhancing resolution, and optimizing contrast
Across different segments, companies are adding new tech-enabled features in their offerings				
	CXOs prioritize the following areas in the digital space for investment Generative AI61% Digital health platforms48% Health informatics35%	CXOs believe that these technologies have the potential to disrupt the existing business model in the CVD space AI/analytics55% Robotic-assisted surgery45% Next-gen CVD imaging platforms45%	CXOs rank these digital features as important for new surgical solutions Robotics platform90% Workflow analytics80% Clinical analytics80% Remote diagnostics76%	CXOs are prioritizing new solutions in the diagnostic imaging space AI/analytics100% Workflow automation96%

Shifting from a product-centric to an end-to-end (E2E) platform mindset benefiting broader care continuum is imperative for success

Trends	Diabetes	Cardiovascular	General surgery	Diagnostic imaging
Business model innovation fuels growth despite cost pressures and shifts in care	New tech-enabled feature is prompting companies to look for alternative business models			
	CXOs are preferring less infrastructure dependent model for their diabetes unit Direct-to-consumer 65% At-risk value-based 52%	With an increasing focus on minimally invasive tech-enabled solutions, CVD is also adopting newer business models Shift to consumer devices Movement into new business models Focus on value-based models	In three years, CXOs see the following business models as the most viable options in the general surgery space Direct purchase 97% Leasing 87% Platform as a service 87% Rentals 87%	CXOs prefer innovative business models in the diagnostic imaging space today Platform as a service 92% Direct purchase 88% Value around the platform 83% Leasing 75% Rentals 38%
Connected ecosystem across care continuum requires broader set of capabilities	Every organization is developing connected solutions to benefit broader care continuum			
	CXOs are confident that their organization’s innovative diabetes care solutions could benefit a wider range of segment propositions. The primary segments poised to benefit include: Wellness solutions 96% Cardiovascular 70% Pharma therapies 35%	CXOs hold the view that their latest CVD solutions could bring advantages to various other segments. The key segments poised for potential benefits include: Diagnostic imaging 76% General surgery 69% Pharma therapies 48%	CXOs anticipate broader benefits across various segments from their organization’s new general surgery solutions. Top beneficiaries include: Cardiovascular 77% Diagnostic imaging 50%	CXOs anticipate broader benefits across various segments from their organization’s new diagnostic imaging solutions. The top segments that could benefit are: Cadiovascular 88% General surgery 83% Wellness solutions 54% IVD 54%

Through the lens of our experts

	Diabetes	Cardiovascular	General surgery	Diagnostic imaging
Key insights	1. Adopt flexible business strategies with the direct-to-consumer (DTC) models 2. Shift from a product-centric to an end-to-end platform mindset 3. Shift from an engineering to an experience-first mindset	1. Enhance upstream care investments 2. Complement downstream portfolios with digital offering 3. Embrace minimally invasive care and connected solutions	1. Upgrade the “hardware” and “software” of general surgery portfolio 2. Explore new business models for general surgical devices 3. Customize to capture the outpatient market	1. Prioritize workflow optimization and scale clinical AI for long-term impact 2. Integrate imaging with procedures 3. Monetize through multiple streams
Role of intelligent technologies	• The future of diabetes care will emphasize the use of intelligent technologies for personalized guidance and early intervention, enhancing consumer engagement and fostering industry collaboration. • This approach not only promises to elevate patient care but also drives the sector toward becoming holistic solution providers.	• Companies will be compelled to develop a connected ecosystem of devices and adopt a continuum of care approach. • Investing in patient-centric research and interdisciplinary collaborations, along with developing comprehensive care strategies and solutions, leads to a dynamic and promising future.	• Intelligent technologies present opportunities to transform early screening and post-operative analysis. • To facilitate these transformations, companies must reimagine their existing technology and advisory ecosystems, including the development of advanced data capabilities.	• The transformation in diagnostic imaging includes hardware, the automation of workflows and the streamlining of data transfer. • To successfully introduce a new device to the market, companies must ensure interoperability, data sharing and a mature digital infrastructure.

What to do next

The MedTech industry is on the precipice of a new frontier, fueled by the extraordinary power of intelligent technologies such as predictive and gen AI. Here are five key actions that companies must take to seize the opportunities offered by enterprise reinvention and intelligent technologies.



Lead with value

Prioritize understanding how gen AI can redefine the company’s value chain.



Reinvent talent and ways of working

Invest in developing new skills and behaviour changes, from the leadership team to each individual employee.



Understand and develop an AI-enabled secure digital core

Establish a robust digital core and data infrastructure to fully leverage the potential of gen AI and enable the continuous creation of new capabilities.



Close the gap on responsible AI

Prioritize responsible AI practices to avoid unintended consequences such as inadvertent biases and discrimination in direct-to-consumer areas and ownership of data used for AI applications.



Drive continuous reinvention

Foster a culture of continuous reinvention and build the capability, approach and tools that enable companies to adapt and innovate while maintaining day-to-day operations.

Authors



Thomas E. Kawalec

Managing Director – Accenture Global Life Sciences MedTech Lead

thomas.e.kawalec@accenture.com

Tom Kawalec is Accenture’s Global MedTech Lead for Life Sciences focusing on strategy, innovation and people development. With 30+ years of consulting experience, he specializes in Enterprise Reinvention, New Business Models, and Digital Products and Services for large-scale Healthcare companies. Tom is passionate about expediting innovative medical technology and pharmaceutical products to market, while improving healthcare experiences through digital transformation. He is based in Chicago, Illinois.



Oliver Richards

Managing Director, Global Medical Technology Strategy Lead for Life Sciences at Accenture

o.richards@accenture.com

Oliver Richards leads Strategy and Commercialization for Accenture Life Sciences Medical Technology. With a Ph.D. in Cell and Molecular Biology and over 15 years of experience in R&D, strategy and consulting, he specializes in designing and implementing innovative growth strategies for the MedTech market. His expertise spans various areas, including general and orthopedic surgery, cardiovascular and diabetes care, in vitro and imaging diagnostics, and digital health. Oliver is based in Milwaukee, Wisconsin.



Selen Karaca-Griffin

Senior Principal – Research Lead, Products, Accenture Research

selen.karaca-griffin@accenture.com

Selen Karaca-Griffin is the Global Research Lead for Accenture Products and Life Sciences leading a team of 30+ researchers globally. She is responsible for developing the industry’s thought leadership agenda, which includes scientific innovation, science and technology convergence, digital health, and market disruptions and their impact on the future of industries. She is based in Boston, Massachusetts.



Garima Mishra

Associate Manager, Life Sciences Research, Accenture Growth and Strategy

garima.j.mishra@accenture.com

Garima Mishra is a member of the Life Sciences Research team and leads MedTech Research. Her research focuses on digital health, technology change, consumerization of healthcare, and market disruptions and their influence on shaping the future of the MedTech industry. She is based in Bangalore, India.

About Accenture

Accenture is a leading global professional services company that helps the world’s leading businesses, governments and other organizations build their digital core, optimize their operations, accelerate revenue growth, and enhance citizen services—creating tangible value at speed and scale. We are a talent- and innovation-led company with approximately 742,000 people serving clients in more than 120 countries. Technology is at the core of change today, and we are one of the world’s leaders in helping drive that change, with strong ecosystem relationships. We combine our strength in technology and leadership in cloud, data and AI with unmatched industry experience, functional expertise, and global delivery capability. We are uniquely able to deliver tangible outcomes because of our broad range of services, solutions and assets across Strategy & Consulting, Technology, Operations, Industry X and Song. These capabilities, together with our culture of shared success and commitment to creating 360° value, enable us to help our clients reinvent and build trusted, lasting relationships. We measure our success by the 360° value we create for our clients, each other, our shareholders, partners and communities.

Visit us at **[accenture.com](https://www.accenture.com)**

About Accenture Research

Accenture Research creates thought leadership about the most pressing business issues organizations face. Combining innovative research techniques, such as data science led analysis, with a deep understanding of industry and technology, our team of 300 researchers in 20 countries publish hundreds of reports, articles, and points of view every year. Our thought-provoking research developed with world leading organizations helps our clients embrace change, create value, and deliver on the power of technology and human ingenuity. For more information,

visit us at **[accenture.com/research](https://www.accenture.com/research)**

Disclaimer

The material in this document reflects information available at the point in time at which this document was prepared as indicated by the date provided on the front page, however the global situation is rapidly evolving, and the position may change. This content is provided for general information purposes only, does not take into account the reader’s specific circumstances, and is not intended to be used in place of consultation with our professional advisors. Accenture disclaims, to the fullest extent permitted by applicable law, any and all liability for the accuracy and completeness of the information in this document and for any acts or omissions made based on such information. Accenture does not provide legal, regulatory, audit, or tax advice. Readers are responsible for obtaining such advice from their own legal counsel or other licensed professionals. This document refers to marks owned by third parties. All such third-party marks are the property of their respective owners. No sponsorship, endorsement, or approval of this content by the owners of such marks is intended, expressed, or implied.